Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

• Status: Not yet recruiting
• Trial end date: 2024-04-30
• Target enrollment: 0
• Participant gender: Female

Summary

In this study, individuals with triple-negative breast cancer will receive either a platinum-based or non-platinum-based preoperative chemotherapy treatment. This study will help us identify which option is the most effective and safe.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
• Treatments: Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel

Criteria

Inclusion Criteria:

• Triple-negative breast cancer

• Stage II and III

Exclusion Criteria:

• Double primaries

• Male breast cancer

• Pregnant or lactating women

• Patients with Eastern Cooperative Oncology Group (ECOG) performance status more than two

• Patients below 18 years old

• Initial surgery of the primary site (excluding diagnostic biopsy)

• Serious concomitant medical illness including clinically significant cardiovascular disease

• Major surgery or trauma in the previous four weeks